Abstract:The TAM family of receptor tyrosine kinases were recently identified to regulate bone homeostasis by controlling osteoblasts and bone formation. Despite extensive knowledge of TAM receptor function in the mononuclear phagocyte system, the role of TAM receptors in osteoclasts remains largely unknown. Here, we identify a physiological regulatory system including MERTK and TYRO3 in osteoclasts controlling RHOA-ROCK-COFILIN/Myosin II signaling, thereby antagonistically regulating osteoclast-mediated bone remodeling to maintain bone homeostasis. Myeloid-specific -mediated deletion of led to increased bone mass in mice. In early stages of RANKL-induced osteoclast differentiation MERTK promotes amoeboid migration mode in osteoclast precursor cells by inducing RHOA-COFILIN-MLC2 pathway leading to increased osteoclast formation. In contrast, TYRO3 inhibits RHOA-ROCK signaling in osteoclast precursor cells thereby inhibiting these processes. Furthermore, we unraveled an inhibitory role of MERTK as well as TYRO3 in osteoclast differentiation and function. In line with this, mice with -mediated deletion of and exhibited an osteoporotic bone phenotype. We found that osteoclast precursor cell morphology dictates its fusion capacity and identified MERTK as a negative regulator of osteoclast fusion. In multinucleated cells, deletion of inhibits actin ring formation by mediating central actomyosin contraction and inactivation of COFILIN. In contrast, spatially well-ordered RHOA activation at adhesion structures, induced by loss of improves osteoclast biomechanotransduction to ameliorate podosome belt formation and enhance osteoclast function. By using a syngeneic breast cancer bone metastasis osteolysis models we identified TYRO3 as a bone protective receptor for osteolytic bone diseases, whereas MERTK represents a pharmacologic accessible target to inhibit osteoclast formation because its stimulatory effects of osteoclast precursors prevail the inhibitory effects on mature osteoclasts. Next to the recently uncovered role of MERTK as a target for osteoanabolic therapy MERTK may represent a one-drug two-target treatment strategy to increase osteoblast function and reduce osteoclast formation for treatments of bone diseases.

Involvement of Siglec-15 in regulating RAP1/RAC signaling in cytoskeletal remodeling in osteoclasts mediated by macrophage colony-stimulating factor

C/Ebp Alpha Regulates Osteoclast Lineage Commitment

Osteal Tissue Macrophages Are Involved in Endplate Osteosclerosis Through the OSM-STAT3/YAP1 Signaling Axis in Modic Changes

Molecular structure, expression, and the emerging role of Siglec-15 in skeletal biology and cancer

RhoA Promotes Osteoclastogenesis and Regulates Bone Remodeling Through Mtor-Nfatc1 Signaling.

Syk, C-Src, the Αvβ3 Integrin, and ITAM Immunoreceptors, in Concert, Regulate Osteoclastic Bone Resorption

Cytoskeletal Dysfunction Dominates in DAP12-deficient Osteoclasts

Class A Scavenger Receptor Exacerbates Osteoclastogenesis by an Interleukin-6-Mediated Mechanism through ERK and JNK Signaling Pathways

The collection of NFATc1-dependent transcripts in the osteoclast includes numerous genes non-essential to physiologic bone resorption

Talin1 and Rap1 Are Critical for Osteoclast Function

Siglec‐F is induced by granulocyte–macrophage colony‐stimulating factor and enhances interleukin‐4‐induced expression of arginase‐1 in mouse macrophages

TAM receptors control actomyosin dynamics in osteoclasts via RHOA-COFILIN-MYOSIN II signaling

RBP-J Imposes a Requirement for ITAM-mediated Costimulation of Osteoclastogenesis

Sigma‐1 receptor attenuates osteoclastogenesis by promoting ER‐associated degradation of SERCA2

Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption

ELMO1 Regulates RANKL-Stimulated Differentiation and Bone Resorption of Osteoclasts

DAP12 Regulates the Osteoclast Cytoskeleton

Osteoclast Signal Transduction During Bone Metastasis Formation

DCIR suppresses osteoclastic proliferation and resorption by downregulating M-CSF and RANKL signaling

Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarization.

Regulatory actions of 3',5'-cyclic adenosine monophosphate on osteoclast function: possible roles of Epac-mediated signaling